Friday, January 05, 2007
Correction: Omnitarg: not so much
Sharp analyst word parses and gets DNA to admit that Omnitarg/pertuzumab didn't meet the primary endpoint in the ovarian cancer trial just mentioned. Between this treatment and perhaps the name change, is there a whitewash underway @ DNA? DNA loses big points for not being candid.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment